Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10345344 | 0.81 | ALDH1A1 (0.30) | TSHRTDP1ALDH1A1 | |
| SCHEMBL10902320 | 0.78 | — | — | |
| SCHEMBL11203236 | 0.74 | MAPT (0.33) | — | |
| SCHEMBL6403891 | 0.74 | HMGCR (0.46) | TSHRTDP1ALDH1A1 | |
| SCHEMBL2916123 | 0.74 | — | — | |
| SCHEMBL8971155 | 0.72 | — | — | |
| SCHEMBL170479 | 0.69 | TSHR (0.32) | TSHRTDP1ALDH1A1 | |
| SCHEMBL11661453 | 0.67 | FDPS (0.36) | TSHRALDH1A1 | |
| SCHEMBL11322321 | 0.67 | — | — | |
| Amylene Hydrate SCHEMBL9619268 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923908-A1 | NOVEL COMPOSITION | Reckitt Benckiser Health Limited (GB) | 2021-12-22 | — | — | EP | claimed |
| CN-113557009-A | Novel compositions | 雷克特本克斯尔健康有限公司 | 2021-10-26 | — | — | CN | claimed |
| WO-2020165578-A1 | NOVEL COMPOSITION | Reckitt Benckiser Health Limited (GB) | 2020-08-20 | — | — | WO | claimed |
| US-10363316-B2 | Pharmaceutical formulation comprising NSAID and cyclodextrin | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2019-07-30 | — | — | US | claimed |
| CN-103260617-B | Comprise the pharmaceutical preparation of NSAID and cyclodextrin | 雷克特本克斯尔医疗保健国际有限公司 | 2016-08-24 | — | — | CN | claimed |
| EP-2651409-B1 | NOVEL PHARMACEUTICAL FORMULATION COMPRISING NSAID AND CYCLODEXTRIN | RECKITT BENCKISER HEALTHCARE INT LTD (GB) | 2016-08-10 | — | — | EP | claimed |
| US-20160008478-A1 | Pharmaceutical Formulation Comprising NSAID And Cyclodextrin | RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| US-9138482-B2 | Pharmaceutical formulation comprising NSAID and cyclodextrin | RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED (GB) | 2015-09-22 | — | — | US | claimed |
| US-20140296342-A1 | Pharmaceutical Formulation Comprising NSAID And Cyclodextrin | RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED (GB) | 2014-10-02 | — | — | US | claimed |
| CN-103260617-A | Novel pharmaceutical formulation comprising NSAID and cyclodextrin | RECKITT BENCKISER HEALTHCARE INT LTD | 2013-08-21 | — | — | CN | claimed |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| WO-2023161452-A1 | SOLID AND ORAL ETOPOSIDE TONIRIBATE COMPOSITIONS | CELLACT PHARMA GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| EP-4233837-A1 | SOLID AND ORAL ETOPOSIDE TONIRIBATE COMPOSITIONS | CellAct Pharma GmbH (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2000001734-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-01-13 | — | — | WO | disclosed |
| EP-0579435-B1 | Cyclodextrin complexation | CYCLOPS H F (IS) | 1999-03-17 | — | — | EP | disclosed |
| US-5472954-A | Combining cyclodextrin with polymer before adding active material | CYCLOPS H.F. (IS) | 1995-12-05 | — | — | US | disclosed |
| US-5324718-A | Complexing with natural and synthetic polymers; high speed drug release | CYCLOPS H.F. (IS) | 1994-06-28 | — | — | US | disclosed |
| EP-0579435-A1 | Cyclodextrin complexation | CYCLOPS h.f. (IS) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | TSHR 4857/4885TDP1 4478/4885ALDH1A1 3916/4885 |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, SI | TSHR 4857/4885TDP1 4478/4885ALDH1A1 3916/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | TSHR 4715/4885TDP1 4483/4885ALDH1A1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.